CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flow from operating activities
Net loss	$ (6,750)	$ (5,467)	$ (4,519)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization	161	161	161
Depreciation	43	41	10
Stock-based compensation	784	369	404
Change in fair value of warrant liability	(1,713)	0	0
(Increase) decrease in assets
Prepaid drug product for testing	184	(405)	(104)
Other current assets	(723)	(79)	(36)
Increase (decrease) in liabilities
Accounts payable and accrued expenses	(146)	375	267
Deferred revenue	12	0	0
Net cash used in operating activities	(8,148)	(5,005)	(3,817)
Cash flow from investing activities
Purchases of furniture, fixtures & equipment	(338)	0	(123)
Net cash used in investing activities	(338)	0	(123)
Cash flow from financing activities
Net proceeds from sale of common stock and warrants	9,007	0	13,812
Net proceeds from exercise of common stock options	0	0	435
Net cash provided by financing activities	9,007	0	14,247
Net increase (decrease) in cash	521	(5,005)	10,307
Cash, beginning of period	8,854	13,859	3,552
Cash, end of period	9,375	8,854	13,859
Non-cash investing activities
Capital expenditures included in accrued expense	$ 247	$ 0	$ 0